- Home
- SCD vs NBTX Comparison
SCD vs NBTX Comparison
Compare SCD & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCD
- NBTX
- Stock Information
- Founded
- SCD 2003
- NBTX 2003
- Country
- SCD United States
- NBTX France
- Employees
- SCD N/A
- NBTX 110
- Industry
- SCD Trusts Except Educational Religious and Charitable
- NBTX Biotechnology: Pharmaceutical Preparations
- Sector
- SCD Finance
- NBTX Health Care
- Exchange
- SCD Nasdaq
- NBTX Nasdaq
- Market Cap
- SCD 259.3M
- NBTX 235.6M
- IPO Year
- SCD N/A
- NBTX 2020
- Fundamental
- Price
- SCD $17.82
- NBTX $5.09
- Analyst Decision
- SCD
- NBTX Strong Buy
- Analyst Count
- SCD 0
- NBTX 2
- Target Price
- SCD N/A
- NBTX $11.50
- AVG Volume (30 Days)
- SCD 62.6K
- NBTX 12.9K
- Earning Date
- SCD 01-01-0001
- NBTX 10-08-2024
- Dividend Yield
- SCD 9.63%
- NBTX N/A
- EPS Growth
- SCD N/A
- NBTX N/A
- EPS
- SCD N/A
- NBTX N/A
- Revenue
- SCD N/A
- NBTX $45,220,186.00
- Revenue This Year
- SCD N/A
- NBTX N/A
- Revenue Next Year
- SCD N/A
- NBTX N/A
- P/E Ratio
- SCD N/A
- NBTX N/A
- Revenue Growth
- SCD N/A
- NBTX 526.17
- 52 Week Low
- SCD $11.33
- NBTX $4.14
- 52 Week High
- SCD $15.87
- NBTX $8.96
- Technical
- Relative Strength Index (RSI)
- SCD 67.07
- NBTX 48.54
- Support Level
- SCD $17.36
- NBTX $4.98
- Resistance Level
- SCD $17.96
- NBTX $5.80
- Average True Range (ATR)
- SCD 0.39
- NBTX 0.34
- MACD
- SCD 0.03
- NBTX 0.02
- Stochastic Oscillator
- SCD 88.14
- NBTX 39.83
About SCD LMP Capital and Income Fund Inc.
Lmp Capital & Income Fund Inc is a United States-based non-diversified, closed-end management investment company. Its investment objective is total return with an emphasis on income. The fund invests in a broad range of equity and fixed-income securities of both the U.S. and foreign issuers. Its long-term investments consists of investments in common stocks, convertible preferred stocks, investments in underlying funds and master limited partnerships.
About NBTX Nanobiotix S.A.
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.